Theresa May confirms to exit as PM on June 7
24 May 2019 – 15:42 | No Comment

After the UK Parliament rejected her Brexit plans for the third time, UK Prime Minister Theresa May has decided to step down as leader of the Conservative Party.
She announced her departure after talks with Graham …

Read the full story »

Energy & Environment

Circular Economy

Climate Change


Home » Diabetes, EU Health

Janssen in diabetes: a lifelong commitment

Submitted by on 29 Sep 2016 – 10:42

With the alarming nature of the human cost of diabetes and the increasing prevalence, Jane Griffiths, Group Chairman, Janssen Europe, Middle East and Africa, Janssen Pharmaceutical Companies of Joohnson & Johnson, reiterates the commitments of the Johnson & Johnson family of Diabetes, and points out that it is critical that industry and policy makers look into new and creative approaches to address the full continuum of the cardiovascular and metabolic disease

The World Health Organization estimates that in 2014, 422 million people had diabetes globally, with the prevalence of the disease having doubled since 1980. (1) European statistics are just as alarming with 60 million people estimated to have diabetes (type 1 and 2) in the European Region, equating to 10.3% of men and 9.6% of women aged 25 years and over. (2) More than 600,000 people die annually as a result of diabetes in Europe, equating to 11% of all deaths in people aged 20-79 years old. (3) Statistics suggest that diabetes is an ever growing epidemic, with projections indicating that over 1 billion people will be living with or at high risk of diabetes globally by 2035.(4)

Beyond the human cost of diabetes, the broader economic impact is considerable. (5) According to the International Diabetes Federation, health expenditure for diabetes was estimated at USD105.5 billion in the European Region: the equivalent of 10% of the European healthcare budget. With such alarming future projections, effective management and prevention of diabetes has never been more important. Few companies are as uniquely positioned as Janssen to address the different aspects of the disease. The Johnson & Johnson Family of Diabetes Companies today touch more than 10 million people with diabetes and share a vision of “Creating a world without limits for people with diabetes.” As a unified, integrated global entity, it has the opportunity to address unmet needs in diabetes and support people living with diabetes and their families.

The Janssen Pharmaceutical Companies of Johnson & Johnson, aim to stimulate the advancement of knowledge about the disease and develop new treatment approaches to potentially prevent the progression of diabetes or cure it. Janssen has already developed important medicines that are currently improving the lives of millions of patients, including those with type 2 diabetes.

Despite recent reports noting that simple lifestyle changes can dramatically lower the chances of developing type 2 diabetes, obesity is still driving the diabetes epidemic in Europe and is estimated to account for approximately 65–80% of new cases of type 2 diabetes. (2) It is also estimated that by 2025, 58.6 million people will have prediabetes in Europe. (6) Early intervention is key in preventing diabetes in high risk populations; however lifestyle changes alone are not always enough. Janssen is therefore focusing on the development of treatments to manage obesity and to prevent diabetes.

Janssen currently has marketing authorisations for canaglifozin (Invokana®) (an SGLT2 inhibitor) and canaglifozin/metformin hydrochloride (Vokanamet®) (a fixed dose combination of SGLT2 inhibitor and metformin) and has recently completed a series of key acquisitions and collaboration agreements to expand the diabetes portfolio, demonstrating a commitment to exploring new therapy areas and driving partnerships.

In November 2015, Janssen obtained worldwide rights, excluding China and Korea, to develop and commercialise oxyntomodulin-based therapies, of which some are showing potential to treat diabetes and obesity. Just a month later, in December 2015, Janssen entered into a research collaboration agreement with Intrexon to discover and develop ActoBiotics® therapies to treat type 2 diabetes, obesity and/or metabolic disorders related to energy dysregulation.

Janssen’s long term commitment to diabetes is further demonstrated through on-going clinical trials, such as the CANVAS, CANVAS-R, and CREDENCE studies, and driving public awareness through projects such as the Janssen Diabetes in the Downturn report. (7)

As the prevalence of diabetes continues to increase, it is critical that industry and policy makers look to new and creative approaches to address the full continuum of cardiovascular and metabolic disease, from risk and screening to diagnosis and treatment.

It is also crucial that industry and healthcare systems work together to provide access to the right medicines and long term support programmes to help prevent diabetes in the first instance, and optimise patient outcomes in the long term

To know more on Diabetes and on Diabetes & Obesity: and


1. World Health Organization. Global report on diabetes. Available at Last accessed May 2016

2. World Health Organization Europe. Diabetes data and statistics, Available at: Last accessed May  2016

3. Jakab, Z., WHO Regional Director for Europe. Delivering for Diabetes in Europe. Plenary Meeting of the European Parliament’s EU Diabetes Working Group, 8 December 2010. Available at: Last accessed May 2016

4. International Diabetes Federation. 2014 Annual Report. Available at: Last accessed May 2016

5. World Health Organization Europe. Diabetes epidemic in Europe. Available at: Last accessed May 2016

6. Pre-diabetes highlighted as problem in Europe. Available at: Last accessed May 2016

7. Janssen. Diabetes in the Downturn report. Available at: Last accessed May 2016